Drugs acting on the cholinergic system can improve or worsen cognitive abilities, and their effects are particularly pronounced in frail elderly individuals and patients with Alzheimer disease. Guidelines are urgently needed on the judicious use of cholinergic drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gardette, V. et al. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study. CNS Drugs 24, 431–442 (2010).
Burns, A. et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J. Psychopharmacol. 20, 732–755 (2006).
Rodda, J. & Walker, Z. Ten years of cholinesterase inhibitors. Int. J. Geriatr. Psychiatry 24, 437–442 (2009).
Herrmann, N. et al. A population-based study of cholinesterase inhibitor use for dementia. J. Am. Geriatr. Soc. 55, 1517–1523 (2007).
Kogut, S. J., El-Maouche, D. & Abughosh, S. M. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy 25, 1729–1735 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Desmarais, J., Gauthier, S. Clinical use of cholinergic drugs in Alzheimer disease. Nat Rev Neurol 6, 418–420 (2010). https://doi.org/10.1038/nrneurol.2010.105
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.105
